Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-17
2008-12-30
Monshipouri, Maryam (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07470670
ABSTRACT:
Novel polypeptides or derivatives comprising cdk2 binding site are disclosed. The novel polypeptides or derivatives have growth suppressive activity. Nucleic acids encoding those polypeptides are also disclosed. The polypeptides identified herein are also useful in methods for treating or preventing cancer. The treatment methods comprise administration of the polypeptide to the patient. The methods also comprise contacting the sample with the above-described polypeptide or derivative, wherein the polypeptide or derivative also comprises a covalently attached detectable moiety, then determining whether the polypeptide or derivative is binding cdk2 from the sample.
REFERENCES:
patent: 5340739 (1994-08-01), Stevens et al.
patent: 5457049 (1995-10-01), Giordano
patent: 5496731 (1996-03-01), Xu et al.
patent: 5521081 (1996-05-01), Inaoka et al.
patent: 5532340 (1996-07-01), Giordano
patent: 5596079 (1997-01-01), Smith et al.
patent: 5597694 (1997-01-01), Munroe et al.
patent: 5654170 (1997-08-01), Klinger et al.
patent: 5807681 (1998-09-01), Giordano et al.
patent: 5840506 (1998-11-01), Giordano
patent: 6297357 (2001-10-01), Giordano
patent: 6663856 (2003-12-01), Giordano
patent: 0 571 911 (1993-12-01), None
patent: 0 666 270 (1995-08-01), None
patent: WO 93/06244 (1993-04-01), None
patent: WO 94/11531 (1994-05-01), None
patent: WO 95/02328 (1995-01-01), None
patent: 99/08700 (1999-02-01), None
Zhu, “A Model for CDK2 in Maintaining Genomic Stability,” Cell Cycle, vol. 3, No. 11, Nov. 2004, pp. 1358-1362.
Claudio, et al., Eighty-Sixth Annual Meeting American Association for Cancer Research, Mar. 18-22, 1995; vol. 36, p. 195, 1164.
Dai, et al., “Small Molecule Inhibotors Targeting Cyclin-Dependent Kinases as Anticancer Agents,” Current Oncology Reports, vol. 6, 2004, pp. 123-130.
Deonarain, “Ligand-targeted Receptor-mediated Vectors for Gene Delivery,” Expert Opinion on Therapeutic Patents, vol. 8, No. 1, 1998, pp. 53-69.
Eck, et al., “Gene-Based Therapy,” Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Ed., 1996, Chapter 5, pp. 77-101.
Hogg, et al., “Detection of Heterozygous Mutations in theRB1Gene in Retinoblastoma Patients Using Single-strand Conformation Polymorphism Analysis and Polymerase Chain Reaction Sequencing,” Oncogene, vol. 7, 1992, pp. 1445-1451.
Lifshitz, et al., “bcrGenes and Transcripts,” Oncogene, vol. 2, 1998, pp. 113-117.
Olofsson, et al., “Abnormal Expression of Cell Cycle Regulators inFUS-CHOPCarrying Liposarcomas,” International Journal of Oncology, vol. 25, 2004, pp. 1349-1355.
Sang, et al., “The Roles of Tumor Suppressors pRb and p53 in Cell Proliferation and Cancer,” Molecular and Cellular Differentiation, vol. 3, No. 1, 1995, pp. 1-29.
Thomas, et al., “A Polymorphic Dinucleotide Repeat in Intron 1 of the Human Tissue Plasminogen Activator Gene,” Human Molecular Genetics, vol. 1, No. 2, May 1992, 138.
Vieweg, et al., “Considerations for the Use of Cytokine-Secreting Tumor Cell Preparations for Cancer Treatment,” Cancer Investigation, vol. 13, No. 2, 1995, 193-201.
Wilson, et al., “Gene Therapy of Cystic Fibrosis Lung Disease Using El Deleted Adenoviruses: A Phase I Trial,” Human Gene Therapy, vol. 5, No. 4, Apr. 1994, pp. 501-519.
Woo, et al., “p130 and p107 Use a Conserved Domain to Inhibit Cellular Cyclin-Dependent Kinase Activity,” Molecular and Cellular Biology, vol. 17, No. 7, Jul. 1997, pp. 3566-3579.
Burgess, et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” The Journal of Cell Biology, vol. 111, Nov. 1990, pp. 2129-2138.
Lazar, et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology, vol. 8, No.3, Mar. 1988, pp. 1247-1252.
Tao, et al., “Studies of Aglycosylated Chimeric Mouse-Human IgG, Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region,” The Journal of Immunology, vol. 143, No. 8, Oct. 15, 1989, pp. 2595-2601.
Li, et al., “The Adenovirus E1A-associated 130-kD Protein is Encoded by a Member of the Retinoblastoma Gene Family and Physically Interacts with Cyclins A and E,” Genes & Development, vol. 7, 1993, pp. 2366-2377.
Gu, et al., “Inhibition of CDK2 Activity In Vivo by an Associated 20K Regulatory Subunit,” Nature, vol. 366, Dec. 16, 1993, pp. 707-710.
Claudio, et al., “p120/pR52 Has Growth Suppressive Properties Similar to yet Distinctive from Those of Retinoblastoma Family Members pRb and p107,” Cancer Research, vol. 54, 1994, pp. 5556-5560.
Baldi, et al., “Genomic Structure of the Human Retinoblastoma-related Rb2/p130 Gene,” Proc. Natl. Acad. Sci. USA, vol. 93, 1996, pp. 4629-4632.
De Luca, et al., “A Unique Domain of pRb2/p130 Acts as an Inhibitor of Cdk2 Kinase Activity,” J. Biol. Chem, vol. 272, 1997, pp. 20971-20974.
Baldi, et al., “The Rb2/p130 Gene Product is a Nuclear Protein Whose Phosphorylation is Cell Cycle Regulated,” Journal of Cellular Biochemistry, vol. 59, 1995, pp. 402-408.
Pines, et al., “Isolation of a Human Cyclin cDNA: Evidence for Cyclin mRNA and Protein Regulation in the Cell Cycle and for Interaction with p34cdc2,” Cell, vol. 58, Sep. 8, 1989, pp. 833-846.
Gibbs, et al., “Pharmaceutical Research in Molecular Oncology,” Cell, vol. 79, Oct. 21, 1994, pp. 193-198.
Koff, et al., “Formation and Activation of a Cyclin E-cdk2 Complex During the G1 Phase of the Human Cell Cycle,” Science, New Series, vol. 257, No. 5077, Sep. 18, 1992, pp. 1689-1694.
Slightom, et al., “Nucleotide Sequence Analysis of 77.7 kb of the Human VβT-Cell Receptor Gene Locus: Direct Primer-Walking Using Cosmid Template DNAs,” Genomics, vol. 20, 1994, pp. 149-168.
Gura, “Systems for Identifying New Drugs Are Often Faulty,” Science, vol. 278, No. 5340, Nov. 7, 1997, pp. 1041-1042.
Song, et al., “Specific Inhibition of Cyclin-Dependent Kinases and Cell Proliferation by Harmine,” Biochemical and Biophysical Research Communications, vol. 317, 2004, pp. 128-132.
Senderowicz, “Small-molecule Cyclin-dependent Kinase Modulators,” Oncogene, vol. 22, 2003, pp. 6609-6620.
Losiewicz, et al., “Potent Inhibition of CDC2 Kinase Activity by the Flavonoid L86-8275,” vol. 201, No. 2, 1994, pp. 589-595.
Morgan, “Cyclin-Dependent Kinases: Engines, Clocks, and Microprocessors,” Annu. Rev. Cell Dev. Biol., vol. 13, 1997, pp. 261-291.
Hsu, et al., “Proliferative Inhibition, Cell-cycle Dysregulation, and Induction of Apoptosis by Ursolic Acid in Human Non-Small Cell Lung Cancer A549 Cells,” Life Sciences, vol. 75, 2004, pp. 2303-2316.
Hirata, et al., “Cloning and Expression of cDNA for a Human Thromboxane A2Receptor,” Nature, vol. 349, Feb. 14, 1991, pp. 617-620.
Crystal, “Transfer of Genes to Humans: Early Lessons and Obstacles to Success,” Science, New Series, vol. 270, No. 5235, Oct. 20, 1995, pp. 404-410.
Vorechovsky, et al., “Isolation of Cosmid and cDNA Clones in the Region Surrounding theBTKGene at Xq21.3-q22,” Genomics, vol. 21, 1994, pp. 517-524.
Harbour, et al., “Abnormalities in Structure and Expression of the Human Retinoblastoma Gene in SCLC,” Science, New Series, vol. 241, No. 4863, Jul. 15, 1988, pp. 353-357.
Zheng, et al., “Development of 124 Sequence-Tagged Sites and Cytogenetic Localization of 217 Cosmids for Human Chromosome10,” Genomics, vol. 22, 1994, pp. 55-67.
Sherr, “Cancer Cell Cycles,” Science, New Series, vol. 274, No. 5293, Dec. 6, 1996, pp. 1672-1677.
Weinberg, “The
McNichol, Jr. William J.
Monshipouri Maryam
Reed Smith LLP
Sbarro Health Research Organization, Inc.
LandOfFree
Peptide inhibitors of cyclin-dependent kinase activity and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide inhibitors of cyclin-dependent kinase activity and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibitors of cyclin-dependent kinase activity and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4045251